CoV inhibitors targeting non-enzymatic SARS-CoV-2 components
Official title: Development of CoV inhibitors against non-enzymatic targets
Funded at Scripps Research Institute, the · NIH-11542058 · Data updated 2026-11-12
A multicenter research effort seeks antiviral ideas that block SARS-CoV-2 parts that don’t work through traditional enzymes, aiming to help people affected by COVID-19.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Scripps Research Institute, the NIH-funded |
| Lab location | 1 site (La Jolla, United States) |
| Project start | May 16, 2022 |
| Project end | August 31, 2028 |
| Funding year | 2026 |
| Award (this year) | $1,197,560 |
| NIH project number | 4U19AI171443-02 |
| Project ID | NIH-11542058 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates are individuals with or at risk for COVID-19 or related coronavirus infections and who participate in clinical or translational research avenues where new antivirals may be tested.
✕Less likely to help
Patients without access to trials or who do not have active infection may not directly benefit from this research.
What this research studies
This project looks for new ways to stop the virus by targeting components like Nsp1 and viral RNA that don’t rely on classic enzymatic activity. Scientists will use biochemical, genetic, structural, and computer-based methods to identify molecules that keep the virus from dampening our immune response. They will also explore advanced antisense strategies to disrupt conserved RNA sequences essential for replication. The work combines several approaches to find potential therapies that could complement existing COVID-19 treatments.
Why it matters
Potential benefit: If successful, the research could lead to new antiviral options that help people recover faster and reduce severe disease.
How similar studies have gone: Previous antiviral efforts targeting non-traditional viral components have yielded promising leads, though this specific approach is relatively novel.
Where this research is happening
-
Scripps Research Institute, the
La Jolla, United States Active
Researchers
- Principal investigator: Garcia-Sastre, Adolfo — Scripps Research Institute, the
- Study coordinator: Garcia-Sastre, Adolfo
Related research
Other NIH-funded projects on the same topics.
-
The Participant Center helps people join and stay in a nationwide health study
A nationwide program to support people in joining, contributing biosamples, and staying connected to a large health study in the United States.
-
Data Sharing and Bioinformatics Core for Viral Systems Biology
A center-led effort to manage, share, and interpret large viral systems biology data using open tools and a community-friendly portal.
-
Germline-targeted HIV vaccines using membrane liposome tech to trigger bnAbs
A new HIV vaccine approach aims to spark broadly neutralizing antibodies by showing MPER on membranes, tested in models and early studies to guide future human trials.
-
Antivirals for hemorrhagic fever viruses like LASV, SFTSV, and EBOV
A multi-institutional effort to find and validate antiviral compounds that block key viral proteins from LASV, SFTSV, and EBOV to help people at risk from serious hemorrhagic fevers.
-
Developing new antivirals for flaviviruses
A research team is working to create oral antiviral drugs targeting flaviviruses to treat infections that affect millions of people.
-
Targeting key coronavirus proteins with new compounds
Researchers are developing new chemical compounds to block important coronavirus proteins, aiming to stop replication across multiple strains for patients who have or may face COVID-19.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.